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and objective functional (timed up and go) and radiographical 
assessments were collected. 
 Results.  Compared with NSM, the BKP group had greater improve-
ments in SF-36 physical component summary (PCS) scores at 1 month 
(5.35 points; 95% CI, 3.41 − 7.30;  P  < 0.0001) and when averaged 
across the 24 months (overall treatment effect 2.71 points; 95% CI, 
1.34–4.09;  P  = 0.0001). The kyphoplasty group also had greater func-
tionality by assessing timed up and go (overall treatment effect  − 2.49 
s; 95% CI,  − 0.82 to  − 4.15;  P  = 0.0036). At 24 months, the change 
in index fracture kyphotic angulation was statistically signifi cantly 
improved in the kyphoplasty group (average 3.13 ° of correction for 
kyphoplasty compared with 0.82 ° in the control,  P  = 0.003). Number 
of baseline prevalent fractures ( P  = 0.0003) and treatment assignment 
( P  = 0.004) are the most predictive variables for PCS improvement; 
however, in patients who underwent BKP, there may also be a link 
with kyphotic angulation. In BKP, the highest quart for kyphotic angu-
lation correction had higher PCS improvement (13.4 points) than the 
quart having lowest correction of angulation (7.40 points,  P  = 0.0146 
for difference). The most common adverse events temporally related 
to surgery ( i.e. , within 30 d) were back pain (20 BKP, 11 NSM) new 
VCF (11 BKP, 7 NSM), nausea/vomiting (12 BKP, 4 NSM), and urinary 
tract infection (10 BKP, 3 NSM). Several other adverse events were 
possibly related to patient positioning in the operating room. 
 Conclusion.  Compared with NSM, BKP improves patient quality 
of life and pain averaged during 24 months and results in better 
improvement of index vertebral body kyphotic angulation. Perioperative 
complications may be reduced with more care in patient positioning. 
 Key words:  balloon kyphoplasty ,  vertebral fracture ,  osteoporosis , 
 kyphosis correction .  
 Level of Evidence: 2 
 Spine  2013 ;38:971–983 
 DOI: 10.1097/BRS.0b013e31828e8e22 
 Study Design.  Multicenter randomized controlled trial. 
 Objective.  To compare the effi cacy and safety of balloon kypho-
plasty (BKP) with nonsurgical management (NSM) during 24 months 
in patients with painful vertebral compression fractures (VCFs). 
 Summary of Background Data.  Recently, several large 
randomized controlled trials have been conducted and reported 
how vertebral augmentation compares with NSM for patients with 
acute VCFs. Few of these trials report on the surgical aspects and 
radiographical vertebral deformity results. 
 Methods.  Adults with 1 to 3 VCFs were randomized within 
3 months of pain to undergo bilateral BKP (n  = 149) or NSM 
(n  = 151). Surgical parameters, subjective quality of life assessments 
 Clinical vertebral fractures affect an estimated 1.4 million individuals worldwide every year.  1  Current therapies for vertebral fractures include nonsurgical and surgi-
cal treatment. Balloon kyphoplasty (BKP) is a percutaneous 
surgical option that aims to reduce pain and disability and 
correct vertebral body deformity using orthopedic balloons. 
Within the current literature, there are well over 300 unique 
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cohorts of at least 10 patients or more with vertebral com-
pression fracture due to osteoporosis or cancer treated with 
kyphoplasty or vertebroplasty. Importantly, within the current 
literature, several studies have demonstrated that kyphoplasty 
and vertebroplasty provide better clinical outcomes to NSM in 
randomized controlled studies  2  –  6  ; however, surgical parameters 
and radiographical outcomes have either been limited or not 
collected or reported. We recently reported 1- and 2-year qual-
ity of life (QOL) outcomes of the fracture reduction evaluation 
(FREE) study, a multinational, randomized controlled trial.  2  ,  3  
The primary objective here is to report the surgical aspects and 
compare the clinical and radiographical outcomes and 30-day 
safety of kyphoplasty treatment with standard NSM. 
 MATERIALS AND METHODS 
 Participants 
 The FREE trial was a randomized, nonblinded trial compar-
ing NSM with BKP, for the treatment of acute painful verte-
bral fractures; details of the participants/protocol have been 
previously reported.  2  ,  3  Participants gave written informed 
consent before enrollment. The protocol and consent forms 
were approved by local ethics committees. 
 Procedures 
 Patients were randomized to either BKP (n  = 149) or NSM 
(n  = 151) as previously described.  2  ,  3  Kyphoplasty surgery was 
to be scheduled no more than 10 days following study entry. 
BKP was performed using introducer tools, infl atable bone 
tamps, and polymethylmethacrylate bone cement, and deliv-
ery devices (manufactured by Medtronic Spine LLC, Sunny-
vale, CA), using a percutaneous, bilateral, transpedicular, or 
extrapedicular approach that has been described in detail else-
where.  2  ,  3  ,  7  ,  8  Intraoperative assessments included procedural 
duration, anesthesia and surgical approach, balloon pressures 
and balloon and cement volumes, intraoperative cement leak-
age, and adverse events (AEs). 
 NSM consisted of analgesics, bed rest, bracing, physiother-
apy, rehabilitation programs, and walking aids according to 
standard practices of participating physicians and hospitals; 
patients who underwent BKP also received these therapies as 
required. All patients were referred for treatment with cal-
cium and vitamin D supplements and antiresorptive or ana-
bolic agents; please refer to previous reports for results of 
these treatment modalities.  2  ,  3  At 24 months, data were avail-
able for 120 patients who underwent BKP and 112 NSM.  2  
 Methods for pain, function, and QOL outcome measures 
have been described previously.  2  ,  3  The timed up and go (TUG) 
test of mobility is an objective, timed test that requires the 
subject to get out of a chair, walk 3 meters away from the 
chair, return, and sit down again, which was assessed at 1, 3, 
6, 12, and 24 months.  9  
 Standing lateral spine radiographs were taken at baseline, 
postoperatively (BKP subjects), 3, 12, and 24 months and read 
centrally (BioClinica Inc, Newtown, PA); 2 radiologists inde-
pendently used semiquantitative grading for fracture determi-
nation  10  and a single reader made quantitative morphomet-
ric measurements from endplate to endplate at the posterior, 
anterior, and midpoint of the vertebral body.  11  Kyphosis angle 
was defi ned as the angle formed by lines drawn parallel to the 
caudal and cranial fractured vertebral body endplates. For ver-
tebral body height, a fractured-to-nonfractured ratio was cal-
culated. The prefracture height was estimated by averaging the 
measurements for the adjacent superior and inferior nonfrac-
tured vertebral bodies up to 4 levels away; otherwise the index 
fracture was considered nonevaluable. All AEs, were reported 
and evaluated by investigators for device or procedure rela-
tionship; AEs were categorized by body system according to 
Medical Dictionary for Regulatory Activities (MedDRA).  12  
 Statistical Analysis 
 Analyses were by intent to treat, including all data avail-
able from the full analysis set; for physical component sum-
mary (PCS), visual analogue scale (VAS), Roland-Morris 
Disability Questionnaire (RMDQ), EuroQol 5 dimension 
(EQ-5D) assessment, TUG and satisfaction outcomes, we 
used repeated-measures analysis of variance using mixed 
models.  2  ,  3  ,  13  ,  14  Patient proportions were compared using the 
stratifi ed Cochran-Mantel-Haenszel  χ 2 test. These analyses 
included randomization stratifi cation factors and baseline 
as covariates. Angulation and vertebral height data were 
assessed for normality using Shapiro-Wilk test statistics and 
 P values for nonparametric tests were used as a result.  P 
values for within group change from baseline are based on 
the signed-rank test and within group change across all time 
points was assessed using the Friedman test; comparison 
between groups at each time point is based on the Mann-
Whitney test. In the quart analyses, kyphosis correction and 
PCS, VAS, EQ-5D and RMDQ data were assessed for nor-
mality using Shapiro-Wilk normality test statistic; Mann-
Whitney nonparametric  P values were used if the normal-
ity test failed, otherwise, the parametric  t test  P values were 
used. No adjustments were made for multiple tests and a  P 
value of 0.05 or less was considered statistically signifi cant. 
 For regression analyses, improvement in PCS (at 3 mo) was 
used as the dependent variable with the following explanatory 
variables (treatment, baseline steroid use, baseline RMDQ, 
VAS and limited activity days, sex, spine T-score, age, base-
line bisphosphonate use, estimated fracture age, number of 
prevalent fractures, and change in kyphotic angulation); base-
line EQ-5D, hip T-score and etiology were not included in 
the model due to high autocorrelation with RMDQ, spine 
T-score and baseline steroid use, respectively. The regression 
model was run fi rst for backward selection of variables with 
 P  ≤ 0.1 with a second run of the model with remaining vari-
ables to obtain adjusted  P values. 
 RESULTS 
 The 2 groups were comparable at baseline for demographic 
variables ( Table 1 ). 
 Procedure Characteristics 
 For the 139 patients who received BKP, on average, kypho-
plasty was performed 7 days (range, 0–41) following 
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
BRS205543.indd   972 29/04/13   9:21 PM
RANDOMIZED TRIAL Kyphoplasty and Nonsurgical Care for VCF • Van Meirhaeghe et al
Spine www.spinejournal.com 973
an average of 2.71 points (95% CI, 1.34 − 4.09;  P  = 0.0001) 
more during the 2-year follow-up with a signifi cant interaction 
between treatment and follow-up time ( P  < 0.0001;  Table 3 ). 
Also, patients assigned to kyphoplasty had statistically sig-
nifi cant improvements in EQ-5D, more back pain relief, less 
Roland-Morris back disability, and were more satisfi ed on a 
20-point Likert scale ( Table 3 ). 
 Kyphoplasty resulted in greater functionality by assessing 
the objective TUG (overall treatment effect  − 2.49 s, 95% CI, 
 − 0.82 to  − 4.15;  P  = 0.0036) during the course of 2 years 
 TABLE 1.  Demographics 
BKP 
n  = 149
NSM 
n  = 151
Patient age (yr), mean (range) 72.2 
(44.5–95.2)
74.1 
(52.8–89.1)
Female, n (%) 115 (77.2) 117 (77.5)
Smoking 
status, n (%)
Never 74 (49.7) 73 (48.3)
Ex 52 (34.9) 56 (37.1)
Current 22 (14.8) 19 (12.6)
Unknown 1 (0.7) 2 (1.3)
Underlying 
etiology, 
n (%)
Primary 
osteoporosis
145 (97.3) 143 (94.7)
Secondary 
osteoporosis
2 (1.3) 6 (4.0)
Multiple myeloma 2 (1.3) 2 (1.4)
Bisphosphonate use (effective at 
baseline), n (%)
13 (8.7) 16 (10.6)
Glucocorticoid use, n (%) 26 (17.4) 26 (17.2)
Index baseline 
fractures per 
patient, 
n (%)
1 100 (67.1) 115 (76.2)
2 34 (22.8) 28 (18.5)
3 15* (10.1) 8 (5.3)
Estimated index fracture age, 
median (IQR)
4.4 (2.4, 8.0) 4.7 
(2.7, 8.9)
Spine T-score (within  − 6/ + 3 mo of 
baseline), n (%)
n  = 135 n  = 128
Normal ( ≥ − 1) 28 (20.7) 20 (15.6)
Osteopenic 
( < − 1 to  ≥ − 2.5)
54 (40.0) 57 (44.5)
Osteoporosis 
( < − 2.5)
53 (39.3) 51 (39.8)
 *One patient had a fourth index fracture identifi ed between screening and 
planned surgery. 
BKP indicates balloon kyphoplasty; NSM, nonsurgical management.
randomization. Most patients were treated using gen-
eral anesthesia (94.2%) and a bipedicular transpedicular 
approach (85.6%) with a median procedure duration of 65.0 
minutes. On average, fi nal bilateral IBT infl ation volumes for 
BKP were 4.8 ( ± 1.9) mL that was consistent with cement 
volume of 4.7 ( ± 2.1) mL. Cement leakage, assessed by phy-
sicians intraoperatively, occurred in 51 of 188 (27.1%) verte-
bral bodies but no AEs were noted intraoperatively in regard 
to leakage ( Table 2 ). Hospitalization duration was a median 
of 4.0 days. 
 Effi cacy Parameters 
 The kyphoplasty group had 5.35 points (95% CI, 3.41–7.30; 
 P  < 0.0001) more on the PCS scale compared with the non-
surgical group at 1 month, (the study primary endpoint) and 
 TABLE 2.  Procedural Characteristics 
Procedure Kyphoplasty
Number of patients treated 139*
Treated fractures per patient, 
n (%)
1 100 (71.9)
2 29 (20.9)
3 10 (7.2)
Procedure duration (min), median (IQR) 65.0 
(49.5, 83.5)
Anesthesia, n (%) General 131 (94.2)
Local 8 (5.8)
Approach, n (%) Extrapedicular 14 (10.1)
Transpedicular 119 (85.6)
Both 5 (3.6)
Unknown 1 (0.7)
Mean IBT infl ation volume 
(mL)  ± SD
Left 2.4  ± 1.0
Right 2.4  ± 0.9
Mean IBT infl ation pressure 
(psi)  ± SD
Left 178  ± 77
Right 180  ± 80
Mean fi nal cement volume 
(mL)  ± SD
Left 2.4  ± 1.1
Right 2.3  ± 1.0
Length of stay (d), median (IQR) 4.0 (2.0, 9.0)
Number vertebral bodies treated 188
Vertebral bodies with cement leak, n (%) 51 (27.1)
Vertebral body leak 
distribution
Disc 37
Soft tissue 6
Venous 5 † 
Posterior 1
Pedicle 1
Foraminal 1
 *Ten balloon kyphoplasty patients did not receive surgery. 
 † For one patient, 3 levels were treated; review of patient postoperative 
radiograph indicated vascular leak at L2 only but counted all 3 levels treated 
as leakages because individual levels not indicated on case report form. 
 SD indicates standard deviation. 
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( Table 3 ). Based on the time required to complete, patients 
may be categorized into 4 groups that are clinically validated; 
freely mobile ( > 0 to  ≤ 10 s), mostly independent ( > 10 to  ≤ 20 
s), variable mobility ( > 20 to  ≤ 30 s), and impaired mobility 
( > 30 s). The difference in categorical change from baseline 
between study groups was statistically signifi cant from 1 to 
6 months ( Table 4 ). 
 Radiographical Results 
 For patients with available plain fi lms at baseline (n  = 140 
for BKP, n  = 133 for NSM),  Figure 1 shows the distribution 
of index levels (those identifi ed as treatment levels) or preva-
lent fractures (all fractures assessed by the core laboratory). 
Prevalent fracture determination identifi ed by 2 independent 
readers were highly concordant (k  = 0.795). For both index 
and prevalent fractures, the majority of fractures occur in the 
transition zone at T12 and L1. Study patients had many more 
prevalent fractures compared with those identifi ed clinically 
( Figure 1 ). 
 For kyphotic angulation of index fractures (see Materi-
als and Methods section and  Figure 2 ), of 188 BKP-treated 
fractures, 164 (87%) fractures were evaluable at baseline 
and the postoperative time point. The postoperative mean 
change from baseline showed an average improvement of 
3.33 ° that was statistically signifi cant ( P  < 0.001). At the 
3-, 12-, and 24-month visit, the angulation changed  − 0.89, 
 − 0.65, and 0.03 ° , compared with postoperative; across 
these time points, differences in angulation were not statisti-
cally signifi cantly different ( P  = 0.284). At 24 months, the 
change from baseline in index fracture kyphotic angulation 
was statistically signifi cantly improved in the kyphoplasty 
group with a correction of 3.13° compared with 0.82° in the 
control group ( P  = 0.003 for comparison). 
 Compared with angulation data, there were less evalu-
able data for assessing vertebral body height ( Figure 2 ); 
only 114 of the 188 treated vertebrae were evaluable. In 
this study the mean baseline anterior vertebral height was 
62.6% ( ± 23.0%) and 61.1% ( ± 21.4%) of the predicted 
height, in the BKP and NSM groups, respectively; simi-
larly, the baseline midvertebral measurement was 65.8% 
( ± 19.5%) and 64.5% ( ± 19.2%). In the BKP group, with 
a mean postoperative anterior gain of 10.0% ( ± 14.1%) 
and a midvertebral change in height of 8.3% ( ± 12.6%), 
this represents an estimated 27% and 25% of lost height 
restored in the BKP group, respectively. At 24 months, ante-
rior and medial measurements in kyphoplasty were statisti-
cally signifi cantly improved 6.7% and 5.9% in the kypho-
plasty group compared with the 1.1% improvement and 
1.9% worsening in the control group ( P  = 0.022 and  P  < 
0.001, respectively). 
 To assess the possible link between BKP kyphotic angula-
tion correction and clinical outcome, we performed a correla-
tion of the change-from-baseline in PCS and kyphotic angu-
lation at 3 months, the fi rst time point in which both of the 
clinical and radiographical parameters were assessed, seem 
to be at steady state and maximize evaluable data. Because 
patients could have multiple fractures, kyphotic angulation  T
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common AEs in this timeframe were back pain (20 BKP, 11 
NSM) new vertebral compression fracture (11 BKP, 7 NSM), 
nausea/vomiting (12 BKP, 4 NSM), and urinary tract infection 
(UTI; 10 BKP, 3 NSM). A few of the back pain AEs (3 BKP 
and 2 NSM) were considered related to treatment received. 
For 6 patients who underwent BKP, nausea/vomiting post-
operative was likely due to anesthesia, whereas in another it 
was attributed to back brace therapy pressing on the stomach; 
none of these events were serious. For 2 BKP patients with 
UTI, the events were possibly due to catheterization during 
the procedure; 1 was a serious AE. Four hematomas occurred 
in the BKP group; 2 were considered procedure-related and 
2 device-related (1 of these was a serious AE). Two nonseri-
ous AEs were related to intubation, hypersensitivity to atracu-
rium besilate and damage to dental bridge ( Table 7 ); the lat-
ter was the only AE noted to have occurred on the operative 
case report form. Nine nonserious AEs were possibly related 
to prone positioning on the operating room table (rib frac-
ture, chest/rib/sternum pain, leg pain, hematoma, headache, 
facial decubitus ulcer). Five patients who underwent BKP had 
new vertebral fractures (4 were serious) considered possibly 
related to cement by the treating physician; however, there 
was no difference in the number of radiographical fractures 
observed at 3 months (27/123 for BKP  vs . 27/100 for NSM; 
 P  = 0.43 for difference). 
 DISCUSSION 
 To provide a context of this research, in September 2012, 
a thorough evaluation of the kyphoplasty literature was 
conducted using PubMed. For clinical studies consisting 
of at least 10 patients with vertebral compression fracture 
due to osteoporosis or cancer treated with kyphoplasty, we 
found what seemed to be 140 unique cohorts and a total 
of 8250 patients treated with kyphoplasty, most reporting 
similar improvements in pain, function, and QOL. The lit-
erature also contains several meta-analyses on kyphoplasty 
and/or vertebroplasty  15  –  24  and a few comparing these sur-
gical therapies to NSM.  5  ,  25  ,  26  Several very large retrospec-
tive studies using Medicare data have also been conducted 
investigating kyphoplasty, vertebroplasty, and nonsurgical 
therapies.  27  –  30  
correction for multiple fractures were summed for individual 
patients. In the BKP group, the correlation was relatively weak 
but statistically signifi cant (Spearman correlation coeffi cient  = 
0.201;  P  = 0.0341). To further evaluate this, patients in the 
bottom and top quarts of kyphotic angulation improvement 
were compared with regard to PCS improvement ( Table 5 ). 
Patients who underwent BKP with highest kyphotic angula-
tion correction had higher PCS improvement (13.4 points) 
than the subgroup having the lowest correction of angulation 
(7.40 points,  P  = 0.0146 for difference). Similarly, patients 
with highest PCS improvement had better kyphosis correc-
tion (5.18 ° ) compared with the subgroup having the lowest 
amount of PCS improvement (1.98 ° ;  P  = 0.0272 for differ-
ence). In similar analyses with the control NSM group, no 
correlation was found and there were no statistically signif-
icant differences in the upper and lower quarts for PCS or 
kyphotic angulation (data not shown). 
 We also analyzed the upper and lower quarts for VAS back 
pain, EQ-5D QOL and Roland-Morris disability in the BKP 
group ( Figure 3 ); angulation correction was statistically sig-
nifi cantly higher in the upper quarts for each of these param-
eters except for RMDQ. 
 To evaluate what variables are the most predictive of PCS 
QOL, we performed a multivariate backward elimination 
regression model.  Table 6 shows the results of the fi nal model 
with remaining variables and adjusted  P values. It is clear 
that the number of baseline prevalent fractures and treat-
ment group are the most predictive variables overall (better 
outcomes in the BKP group and better outcomes in patients 
with fewer prevalent fractures at baseline) and fracture age 
to a lesser degree (younger fractures correlating to better out-
comes). Similarly, within each treatment group, the number of 
prevalent fractures was most predictive. Additionally, in the 
BKP group, the baseline pain score and change in kyphotic 
angulation remained with adjusted  P values of  P  = 0.0709 
and  P  = 0.0727, respectively. In the NSM group, the esti-
mated fracture age remained with  P  = 0.0446. 
 Intraoperative Safety 
 To assess safety events temporally related to surgery, we report 
all AEs occurring within the fi rst 30 days ( Table 7 ). The most 
 Figure 1.  Histogram of index and prevalent fractures for 
BKP and NSM groups, combined. BKP indicates balloon 
kyphoplasty; NSM, nonsurgical management. 
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 Figure 2.  Index vertebral body kyphotic angulation correction and height restoration. Means and 95% confi dence intervals are shown for balloon 
kyphoplasty and nonsurgical management for (A) kyphotic angulation of index fractures; (B) index fracture anterior height as a percent; (C) index frac-
ture midvertebral height as a percent; (D) index fracture posterior height as a percent. Group comparison  P values are shown for each time point. The 
asterisk (*) indicates a statistically signifi cant improvement from baseline postoperatively ( P  < 0.001). The Friedman  P value represents change across all 
time point for the BKP group. BKP indicates balloon kyphoplasty; NSM, nonsurgical management; postop indicates postoperative; NE, not evaluated. 
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 Within the current literature we have found several ran-
domized clinical trials comparing either kyphoplasty or ver-
tebroplasty to nonsurgical management (NSM),  2  –  4  ,  6  ,  31  –  34  and 
several reports that compare the cost-effectiveness of these 
procedures compared with NSM.  4  ,  29  ,  35  –  37  Thus, mounting 
evidence document the benefi ts of kyphoplasty and vertebro-
plasty over standard NSM. 
 Although 2 randomized trials concluded that vertebro-
plasty was no different than a “sham” intervention in back 
pain and disability,  38  ,  39  it is important to note that several 
limitations make it hard to draw defi nitive conclusions.  40  ,  41  
Further trials comparing sham with kyphoplasty and/or ver-
tebroplasty, designed to address these limitations, are needed. 
However, it is important to note in this study, for most crite-
ria, maximal benefi t, and stabilization for each group occurs 
between 3 and 12 months, and we have demonstrated bet-
ter pain and EQ-5D QOL outcomes compared with NSM 
throughout 2 years,  2  an outcome not consistent with placebo 
effects. 
 To date none of the major RCTs for kyphoplasty or ver-
tebroplasty have described detailed radiographical outcomes. 
Therefore, we have extended our previous results to describe 
the surgical parameters, vertebral body kyphosis correction 
and height restoration, the objective TUG test results, and 
intraoperative safety and analyses exploring the link between 
vertebral body anatomy correction and QOL. 
 The postoperative mean change from baseline showed an 
average improvement of 3.33 ° in the BKP that was statistically 
signifi cantly different from the baseline measurement ( P  < 
0.001); across all follow-up time points, differences in index 
fracture kyphotic angulation correction were not statistically 
signifi cantly different ( P  = 0.284), indicating that postopera-
tive deformity correction is maintained during the 24 months 
of follow-up. The correction was, not surprisingly, better in the 
BKP group compared with the NSM group at all time points 
through 24 months. Overall, the fi nal kyphosis correction/ T
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 Figure 3.  Kyphotic angulation for upper and lower quarts of PCS, VAS, 
EQ-5D, and RMDQ. The fi gure shows the kyphotic angulation im-
provement for the upper and lower quarts for each clinical outcome 
measure. For each assessment, Shapiro-Wilk normality test was con-
ducted. Based upon this test result, Mann-Whitney  U nonparametric 
test  P values are shown for SF-36 PCS and parametric  t test  P values 
are shown for VAS, EQ-5D, and RMDQ. EQ-5D indicates EuroQol 5 
dimension; VAS, visual analogue scale; RMDQ, Roland-Morris Dis-
ability Questionnaire; PCS, physical component summary. 
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dictors of PCS outcome. A few studies have demonstrated a 
possible connection between angulation and pulmonary func-
tion,  49  ,  50  but few studies have demonstrated a clinical benefi t 
of height restoration. To our knowledge, no MCID has been 
established for kyphosis correction and the clinical relevance 
of the average 2.3 ° -treatment effect of BKP over NSM at 24 
months is dubious. However, we observed a relatively weak 
correlation between PCS and kyphosis correction in the BKP 
group (Spearman correlation coeffi cient  = 0.201;  P  = 0.0341) 
and kyphosis correction remained in the multivariable back-
ward elimination regression ( P  = 0.0727). Moreover, patients 
with the highest amount of kyphosis correction had approxi-
mately 6 points more PCS improvement at 3 months; putting 
this in a clinical perspective, 3.5 points is the MCID for PCS.  48  
Furthermore, when comparing the upper and lower quarts 
for PCS, EQ-5D and back pain, those with greater clinical 
improvement had more kyphosis correction at the treated ver-
tebrae ( Figure 3 ). Fracture mobility, fracture age, patient posi-
tioning (bolstering), IBT use and possibly anesthesia type are 
important parameters that may infl uence fracture reduction.  51  
Techniques of vertebroplasty, primarily attributed to postural 
reduction, may also yield height restoration  52  ,  53  but nonethe-
less, 1 small vertebroplasty  versus kyphoplasty RCT showed 
similar pain outcomes for the 2 procedures but better height 
in BKP.  54  Taken all together, our results suggest that BKP treat-
ment and fewer prevalent fractures at baseline are the most 
important predictors for providing better PCS QOL outcomes. 
However, our data also suggest, to a lesser extent, that treat-
ing physicians should also consider all parameters in achieving 
maximal vertebral anatomy correction when performing verte-
bral augmentation which is in line with orthopedic principles. 
 We previously reported and discussed the long-term seri-
ous AEs and those related to device or procedure (1 patient 
with UTI and subsequent spondylitis, 1 patient with a hema-
toma and 1 with anterior cement migration).  2  ,  3  With regard 
to AEs that occurred within 30 days, the most common were 
nausea, back pain, and UTIs ( Table 7 ). A few of these were 
considered related to treatment received; nausea, mostly 
attributed to anesthesia, is not surprising because 94% of 
patients who underwent BKP were treated using general anes-
thesia. Recently, there is a trend toward more local anesthesia 
use, likely due to more interventional radiologists performing 
BKP, but this is a challenge in elderly patients with scoliosis 
and facet arthritis. Similarly, a few of the UTIs, common in 
the elderly, were exacerbated by catheterization. There were 
9 nonserious AEs possibly related to prone positioning in the 
operating room; this safety data suggest the need for extreme 
care in preparing these elderly patients for surgery. A few new 
fractures were considered possibly related to bone cement; 
however, there was no statistically signifi cant difference in the 
number of patients with new fractures or adjacent fractures.  2  
Finally, regarding cement leakages, those into the venous 
system or within posterior elements are typically of most 
concern. A few such patients in our study were regarded as 
asymptomatic because no intraoperative AEs were noted by 
investigators and in reviewing all AEs throughout the study 
for these patients, only a new fracture AE was considered 
vertebral body height restoration in our study is lesser to 
some extent when compared with other results such as that 
by Voggenreiter  et al  42  ; this may be due to the multicenter 
nature of our study, larger sample size, and the independent 
radiographical core lab assessments, which minimizes reader 
bias. In this study the mean preoperative anterior vertebral 
height in the BKP group was approximately 63% of the pre-
dicted height, with a mean postoperative gain of 10%, repre-
senting an estimated 27% of lost height restored; this result is 
similar to other published studies.  43  ,  44  It will be of interest in 
future studies to understand deformity correction outcomes 
with new infl atable bone tamp technologies that are made of 
less compliant materials. 
 The difference between the treatment groups met the 0.08-
point minimally clinically important difference (MCID) for 
EQ-5D at all time points ( Table 3 ).  45  Similarly for pain, the 
0.83 point difference at 24 months is a 29% difference; a 
25% to 30% difference is also considered clinically relevant.  46  
The objective TUG test matched fairly well with the subjec-
tive RMDQ; improvement in the clinically relevant TUG cat-
egories  9  was signifi cant through 6 months and the categories 
themselves were marginally signifi cant at 12 months ( Table 4 ). 
For RMDQ, using 2 to 3 points as the MCID,  47  results were 
statistically and clinically signifi cant through 12 months and 
marginally statistically signifi cant at 24 months. For PCS, 
using the MCID of 3.5 points, the results were both statisti-
cally and clinically relevant through 6 months.  48  In our study, 
in multivariable backward elimination regression, it was clear 
that treatment assignment ( P  = 0.004) and the number of 
baseline prevalent fractures ( P  = 0.0003) were the best pre-
 TABLE 6.  Regression Analysis for Explanatory 
Variables for Improvement in PCS 
Cohort
Number of 
Observations Variables Remaining  P 
All Data 206 Number of prevalent 
fractures
0.0003
Treatment group 0.0040
Estimated fracture age 0.0548
Kyphoplasty 111 Number of prevalent 
fractures
0.0064
Baseline VAS 0.0709
Change in kyphotic 
angulation
0.0727
Sex 0.1191
NSM 91 Number of prevalent 
fractures
0.0444
Estimated fracture age 0.0446
Baseline limited 
activity (d)
0.2605
 VAS indicates visual analogue scale; NSM, nonsurgical management; PCS, 
physical component summary. 
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 TABLE 7.  Adverse Events Within 30 Days of 
Surgery/Enrollment 
Number of Patients
Kyphoplasty 
(n  = 149)
NSM 
(n  = 151)
With any AEs within 30 d* 94 55
With serious AEs within 30 d* 24 17
Blood and lymphatic system 
disorders |anemia
1 1
Cardiovascular disorders
 Atrioventricular block 
 (preoperative)
1
 Arrhythmias 4
 Dizziness 1
 Myocardial infarction 1†
 Cardiac arrest 1 1
 Heart failure 1
Ear and labyrinth disorders 1
Endocrine disorders 1 2
Eye disorders 1 1
Gastrointestinal disorders
 Constipation 3 5
 Gastritis 1 1
 Diarrhea 2 2
 Nausea and/or vomiting 12‡ 4
 Other 5 5
General disorders
 Anorexia 1
 Pyrexia 3 1
 Drug intolerance 2 2
Hepatobiliary disorders|
hepatorenal syndrome
1
Immune system disorders
 Dermatitis 2
 Drug hypersensitivity 1§ 1§
 Conjunctivitis 1
Infections
 Sepsis 1 1
 Wound infection 1 ¶ 
 Urinary tract infection 10 || 3
 Other 5 4
Injury, poisoning, and procedural complications
 Dental trauma 1**
 TABLE 7.  ( Continued ) 
Number of Patients
Kyphoplasty 
(n  = 149)
NSM 
(n  = 151)
 Hematoma 5††
 Laceration 2 1
 Other 1 1
Metabolism and nutrition disorders 3 3
Musculoskeletal disorders
 Myalgia 1‡‡
 Fracture, leg 1 1
 Fracture, rib 1§§ 1
 Fracture, vertebral 11¶¶ 7
 Pain, back 20 |||| 11 |||| 
 Pain, chest/ribs/sternum 4*** 1
 Pain, hip 4
 Pain, leg 6†††
 Pain, shoulder 3 2
 Other 5 1
Neoplasm 1
Neurological disorders
 Headache 1‡‡‡
 Myalgia 1
 Pain, hip 1
 Pain, leg 2
 Modifi cation in 
 neurological examination
3
 Paresthesia 1
 Syncope 1
 Sciatica 1 2
 Other 3 2
Psychiatric disorders 6 2
Renal disorders 1 1
Reproductive disorders 1 1
Respiratory disorders
 Dyspnea 1 1
 Pneumonia 3 3
 Other 3
Skin disorders
 Decubitus ulcer 1§§§ 2
 Other 5 3
(Continued ) (Continued )
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may have infl uenced patient responses or radiologist assess-
ments. The study, powered to detect differences between groups 
in SF-36 PCS at 1 month, may not be adequately powered to 
detect differences in other radiographical, clinical, or safety out-
comes. The radiographical data collection and therefore, the 
analysis, had several limitations. Due to the multicenter nature 
of the trial, the quality of the fi lms and use of standard markers 
to control magnifi cation error was variable despite the use of 
a detailed radiographical protocol and training. Therefore, for 
height restoration, we had to rely on normal adjacent vertebrae 
to estimate height. We used standard thoracic and lumbar fi lms 
to capture all vertebral bodies from T5–L5; because most frac-
tures occur in the transition zone, these areas are often on the 
extreme ends of the fi lms where parallax is maximized and the 
next normal vertebrae may not be captured on the same fi lm. 
Adjacent prevalent fractures ( Figure 1 ) also diminished these 
evaluations. As a result, compared with vertebral body height 
restoration data, there was more evaluable radiographical data 
for kyphotic angulation of index fractures; this is because this 
measurement does not necessitate controlling for magnifi ca-
tion error and does not depend on including normal adjacent 
vertebrae. Finally, the analyses of clinical outcomes and radio-
graphical results (kyphotic angulation correction) suggest a 
link but were exploratory in nature and less predictive than 
other variables such as baseline prevalent fracture; more stud-
ies are required where the study design is appropriately focused 
to confi rm this hypothesis. 
CONCLUSION
 We conclude that, compared with NSM, BKP rapidly reduces 
pain and improves function, disability, and QOL during the 
course of 2 years and the reduction in pain, EQ-5D QOL, 
patient satisfaction, and kyphotic angulation remain statisti-
cally signifi cant at all time points. Perioperative complications 
could be minimized with more care in patient positioning. 
cement related. Thus, we have found, similar to those of sev-
eral meta-analyses,  16  ,  18  ,  55  that such leakages occur least often 
( e.g. , compared with intradiscal leakages) and that clinically 
symptomatic leakages are relatively rare. It is thought that 
creation of a void with the IBT with a known volume for 
cement fi ll and the compaction of cancellous bone along with 
use of radiopaque, viscous, cement and fl uoroscopy use dur-
ing cementation can help reduce such leakages.  8  ,  56  
 This is the largest randomized trial of surgical treatment for 
vertebral fractures, with relatively high rates of follow-up for 
2 years and assessment of multiple clinical and radiographical 
endpoints compared with standard practice; however, our study 
has several limitations. Knowledge of treatment assignment 
 TABLE 7.  ( Continued ) 
Number of Patients
Kyphoplasty 
(n  = 149)
NSM 
(n  = 151)
Vascular disorders
 Peripheral edema 3 3
 Hypertension 1 1
 Other 3 1
 *Patients may have had multiple AEs; all MedDRA categories and lower 
level terms are listed for AEs occurring within 30 days; an AE was serious if 
it resulted in death, life-threatening injury, or permanent impairment or if it 
required extended hospital stay or intervention to prevent impairment. 
 †AE was serious, occurred prior to planned surgery and resulted in death. 
 ‡Six patients had nausea/vomiting postoperative likely due to anesthesia, in 
another patient it was attributed to back brace pressing on stomach; none of 
these events were serious. 
 §One patient who underwent BKP had hypersensitivity to atracurium besi-
late for intubation and one patient who underwent NSM had hypersensitivity 
to tramadol; neither AE was serious. 
 ¶One patient had swollen wounds at the incision site; the AE was not serious 
and did not require treatment. 
 || Two patients had UTIs possibly due to catheterization during the proce-
dure; 1 was a serious AE. 
 **One patient had damage to bridge while intubating; the AE was not seri-
ous. 
 ††Two patients had hematomas considered device related (1 was serious), 
whereas 2 had hematomas considered procedure related (1 at incision site 
and the other on chest due to prone positioning—neither were serious). 
 ‡‡Event was considered procedure related but was not serious. 
 §§One BKP had a rib fracture (not serious) due to positioning on OR table. 
 ¶¶Five patients who underwent BKP had new vertebral fractures (4 serious) 
considered possibly related to cement by local investigator. 
 || || Three patients who underwent BKP (none were serious) and 2 patients 
who underwent NSM (1 serious) had back pain related to treatment. 
 ***Three patients who underwent BKP had pain likely due to prone position-
ing on OR table (none were serious). 
 †††Two patients who underwent BKP had leg pain that may have been due 
to prone positioning on OR table (none were serious). 
 ‡‡‡Headache possibly due to prone positioning. 
 §§§One patient had pressure sores on face likely due to positioning on OR 
table (not serious). 
 AE indicates adverse event; NSM, nonsurgical management; UTI, urinary 
tract infection. 
 ➢  Key Points 
    Compared with the control group, BKP rapidly im-
proves pain, function, disability, and QOL during the 
course of 2 years. 
    Number of baseline prevalent fractures and treat-
ment assignment are the most predictive variables 
for SF-36 PCS QOL improvement. 
    At 24 months, the change from baseline in index frac-
ture kyphotic angulation was statistically signifi cantly 
improved in the kyphoplasty group; on average 3.1 ° 
of correction for kyphoplasty compared with 0.8 ° in 
the control. 
    Patients who underwent BKP in the top 25% for 
kyphotic angulation correction had higher PCS 
improvement (13.4 points) than those in the bottom 
25% (7.40 points). 
    Assessment of 30 day AEs suggests that periopera-
tive complications could be minimized with more 
care in patient positioning. 
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